Netarsudil-latanoprost (Roclanda®). HTA ID: 23076

Assessment Status Rapid Review Complete
HTA ID 23076
Drug Netarsudil-latanoprost
Brand Roclanda®
Indication Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intraocular pressure reduction.
Assessment Process
Rapid review commissioned 20/12/2023
Rapid review completed 22/02/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that netarsudil-latanoprost be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.